Ipsen's Onivyde regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA

13.02.2024 - Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically meaningful improvements in overall survival and progression-free survival versus ...

Related Keywords

Taiwan ,California ,United States ,San Francisco ,France ,Australia ,Taipei ,T Ai Pei ,American ,America ,Rachel Reiff ,Julie Fleshman ,Zev Wainberg ,Ipsen Biopharmaceuticals Inc ,American Cancer Society ,Pancreatic Cancer Action Network Pan ,Ucla Gi Oncology Program ,National Comprehensive Cancer Network ,Drug Administration ,Pancreatic Cancer Action ,National Comprehensive Cancer ,Ipsen Cares ,Ipsen Fast Track ,North America ,South America ,Rare Disease ,Sponsored Leveli American Depositary Receipt ,Lung Disease ,Hypersensitivity Reaction ,Fetal Toxicity ,Reproductive Potential ,Ipsen Biopharmaceuticals ,Prescribing Information ,French Autorit ,Des March ,Universal Registration ,Cancer Society ,Cancer Facts ,Open Label Phase ,Liposomal Irinotecan ,Metastatic Pancreatic Ductal Adenocarcinoma ,Cancers Symposium ,Ipsen Chart ,Psen Kurs ,Psen Aktie ,